Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
informację o ogólnej liczbie głosów
Proxy Solicitation & Information Statement Classification · 72% confidence The document provides detailed information on the total number of shares and voting rights by share class in advance of an Extraordinary General Meeting. It is part of the informational materials sent to shareholders to prepare for and solicit votes at the meeting, rather than reporting results or issuing new shares. This matches the Proxy Solicitation & Information Statement definition.
2026-05-22 Polish
wzór instrukcji wykonywania prawa głosu przez pełnomocnika
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an instruction for voting by proxy at the Ordinary General Meeting (AGM) of Captor Therapeutics S.A. on June 19, 2026. It lists agenda items and proposed resolutions with voting checkboxes for a proxy holder. This is not the annual report itself, nor the results post-meeting, but materials sent to shareholders to solicit and guide their votes. Therefore it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-05-22 Polish
wzór pełnomocnictwa
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a proxy authorization form (Formularz Pełnomocnictwa) allowing shareholders to appoint a proxy to vote at the company’s Ordinary General Meeting on June 19, 2026. This is part of materials sent to shareholders to solicit votes and proxies for the AGM, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-22 Polish
sprawozdanie Rady Nadzorczej Spółki za rok 2025
Governance Information Classification · 90% confidence The document is a formal Polish Supervisory Board Report (“Sprawozdanie Rady Nadzorczej”) detailing the legal basis, composition, committees, independence assessments, internal controls, and governance practices of the Supervisory Board for the 2025 financial year. It is not an Annual Report (10-K/annual report), nor an announcement of a meeting or proxy materials; rather it focuses on the company’s governance structure and practices. This best fits the Governance Information category (CGR).
2026-05-22 Polish
raport niezależnego biegłego rewidenta z wykonania usługi atestacyjnej dającej racjonalną pewność w zakresie oceny sprawozdania o wynagrodzeniach
Audit Report / Information Classification · 90% confidence The document is an independent auditor’s report (Raport niezależnego biegłego rewidenta) providing an attestation on the completeness of the company’s remuneration report under Polish public offering law. It is a standalone audit/assurance report rather than a full annual or interim financial statement, management commentary, or mere announcement. This matches the definition of a standalone Audit Report / Information.
2026-05-22 Polish
sprawozdanie o wynagrodzeniach sporządzone przez Radę Nadzorczą Spółki za rok 2025
Remuneration Information Classification · 95% confidence The document is a statutory annual Remuneration Report (“Sprawozdanie o wynagrodzeniach”) covering detailed compensation of Management Board and Supervisory Board members for the year 2025, prepared pursuant to Article 90g of the Polish Public Offering Act. It focuses entirely on executive and director pay, listing fixed and variable components, and governance‐mandated disclosures about remuneration policy and actual awards. This matches the Remuneration Information category.
2026-05-22 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.